This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
PBMs, insurers, pharmacompanies, and hospitals don’t want to give up their profits even if it’s better for the general population. The company has hired former senior health regulators to help it navigate America’s healthcare bureaucracy. . Not if it affects their bottom line.
Jayne discusses changes in the lifescience and specialty pharmacy industries since the COVID-19 pandemic began. She highlights three key trends that pharmacompanies, plan sponsors, and others will consider as we head to the upcoming Asembia Specialty Pharmacy Summit (October 26 to 29 in Las Vegas).
The past two years have shone a spotlight on the UK lifesciences industry. Pharmacompanies are now household names, having been thrust into the public’s consciousness after dominating the headlines through the pandemic. An industry that will forever play a greater role in our everyday lives. About the author.
One widely adopted and valuable health technology is telecommunications, which allows both physicians to maintain a high level of care than they otherwise could have during the pandemic and pharmacompanies to continue clinical trials. However, it’s not just GPs and patients who were affected, pharmacompanies were impacted as well.
Looking to the year ahead, here are some key challenges and solutions to keep in mind for a successful 2023 for recruiting, hiring, and retaining talent within a pharmaceutical company. A top 10 pharmacy school doesn’t always breed the best candidates, nor does having experience working at a “top-tier” company. Recruiting.
In October 2022, Xtalks celebrated two decades of bringing diverse stakeholders in the lifescience industry together through first holding physical events, then soon after, hosting exclusively online events. In that time, we’ve gone from running 25 webinars each year to over 400, working with more than 800 expert speakers each year.
From Pharmacy School to Pharmacovigilance Ashish’s journey into pharmacovigilance began during his pharmacy school days, where an internship first exposed him to the field. Driven by a deep-rooted passion for patient safety, Ashish provides a personal glimpse into his everyday responsibilities and the evolving landscape of his field.
No more ‘business as usual’ for pharma’s customer engagement. Lifesciencescompanies need to rethink their customer engagement paradigms in light of changing customer preferences. Pharmacompanies will need to continually rethink what works and not be afraid to experiment with solutions they’ve never tried before.
Among its services, Lilly said LillyDirect provides disease management resources that include access to independent healthcare providers, personalized support and direct delivery of select Lilly medications to homes via third-party pharmacy dispensing services.
Gaurav Kapoor, co-founder and executive vice president of Indegene, tells pharmaphorum how pharma can take lessons from the entertainment industry and prepare for the Metaverse to enhance content engagement. Pharmacompanies’ customer communication methods require reimagining as technology progresses. About the author.
Pharma leaders fear extreme vulnerability in end-to-end supply chain as pandemic continues, according to global survey. Explore how pharmacompanies and industry leaders can reset for growth in the lab beyond coronavirus in Pharma IQ ’s fourth annual edition of Smart Lab Digital. Save your early bird seat now.
It is specifically approved as an interchangeable biosimilar, which means it may be substituted for the original product at the pharmacy level by a pharmacist without the need for a healthcare professional to prescribe the change. This gives it a significant edge over a simple biosimilar designation.
Though the above offerings will benefit African patients and the system overall, garnering partners helps companies such as Philips improve health networks in ways it couldn’t otherwise do. Collaborating with pharma. Kroezen has a master’s degree in business science from the University of Twente. About the author.
Co-chaired by Lord James O’Shaughnessy and Professor Mike Bewick, former deputy national medical director of NHS England (present online), the NHS Innovation and LifeSciences Commission Report launch took place at One Great George Street, Westminster, on 12th December 2022. In short, some people simply want to manage their own health.
The first ten drugs to undergo Medicare drug price negotiations were chosen based on criteria determined by Medicare, which include that they be sold in pharmacies, not have significant generic competition and have been on the market for at least nine years (13 years for more complex biologics).
US Senator Bernie Sanders, who chairs the Health, Education, Labor, and Pensions (HELP) Committee, managed to bring CEOs of major American pharmacompanies to a committee hearing to discuss exorbitant US drug pricing. Scapegoating PBMs has been an industry default in trying to explain exorbitant US drug prices.
They also blamed pharmacy benefit managers (PBMs), third-party companies that serve as pharma middlemen, who select which drugs receive insurance coverage and charge drug companies rebates and fees for covering them. The companies are often integrated with pharmacies and insurers.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content